Literature DB >> 21742107

Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D).

Sheng-Chia Chung1, Mark A Hlatky, Roslyn A Stone, Jamal S Rana, Jorge Escobedo, William J Rogers, Joyce T Bromberger, Sheryl F Kelsey, Maria Mori Brooks.   

Abstract

BACKGROUND: The longitudinal association between obesity, weight variability, and health status outcomes is important for patients with coronary disease and diabetes.
METHODS: The BARI 2D was a multicenter randomized clinical trial designed to evaluate treatment strategies for patients with both documented stable ischemic heart disease and type 2 diabetes. We examined BARI 2D participants for 4 years to study how body mass index (BMI) was associated with health status outcomes. Health status was evaluated by the Duke Activity Status Index (DASI), RAND Energy/fatigue, Health Distress, and Self-rated Health. Body mass index was measured quarterly throughout follow-up years, and health status was assessed at each annual follow-up visit. Variation in BMI measures was separated into between-person and within-person change in longitudinal analysis.
RESULTS: Higher mean BMI during follow-up years (the between-person BMI) was associated with poorer health status outcomes. Decreasing BMI (the within-person BMI change) was associated with better Self-rated health. The relationships between BMI variability and DASI or Energy appeared to be curvilinear and differed by baseline obesity status. Decreasing BMI was associated with better outcomes if patients were obese at baseline but was associated with poorer DASI and Energy outcomes if patients were nonobese at baseline.
CONCLUSIONS: For patients with stable ischemic heart disease and diabetes, weight gain was associated with poorer health status outcomes, independent of obesity-related comorbidities. Weight reduction is associated with better functional capacity and perceived energy for obese patients but not for nonobese patients at baseline.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21742107      PMCID: PMC3141323          DOI: 10.1016/j.ahj.2011.03.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  25 in total

1.  The spread of the obesity epidemic in the United States, 1991-1998.

Authors:  A H Mokdad; M K Serdula; W H Dietz; B A Bowman; J S Marks; J P Koplan
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

2.  The effect of obesity on quality of life in patients with diabetes and coronary artery disease.

Authors:  Mark A Hlatky; Sheng-Chia Chung; Jorge Escobedo; William B Hillegass; Kathryn Melsop; William Rogers; Maria M Brooks
Journal:  Am Heart J       Date:  2010-02       Impact factor: 4.749

3.  Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause.

Authors:  C Scheidt-Nave; H Bismar; G Leidig-Bruckner; H Woitge; M J Seibel; R Ziegler; J Pfeilschifter
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

Review 4.  Overweight, obesity, and health risk.

Authors: 
Journal:  Arch Intern Med       Date:  2000-04-10

5.  Modeling mood variation associated with smoking: an application of a heterogeneous mixed-effects model for analysis of ecological momentary assessment (EMA) data.

Authors:  Donald Hedeker; Robin J Mermelstein; Michael L Berbaum; Richard T Campbell
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

Review 6.  Is weight loss the optimal target for obesity-related cardiovascular disease risk reduction?

Authors:  Robert Ross; Peter M Janiszewski
Journal:  Can J Cardiol       Date:  2008-09       Impact factor: 5.223

Review 7.  The danger of weight loss in the elderly.

Authors:  S L Miller; R R Wolfe
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

Review 8.  The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature.

Authors:  Susan L Dennett; Kristina S Boye; Nicole R Yurgin
Journal:  Value Health       Date:  2008 May-Jun       Impact factor: 5.725

9.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

10.  Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 17.152

View more
  2 in total

Review 1.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24

2.  Duke Activity Status Index for cardiovascular diseases: validation of the Portuguese translation.

Authors:  Mariana A Coutinho-Myrrha; Rosângela C Dias; Aline A Fernandes; Christiano G Araújo; Mark A Hlatky; Danielle G Pereira; Raquel R Britto
Journal:  Arq Bras Cardiol       Date:  2014-02-17       Impact factor: 2.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.